Literature DB >> 14499260

Perforin and the granule exocytosis cytotoxicity pathway.

Marta Catalfamo1, Pierre A Henkart.   

Abstract

Perforin defects have been identified in humans with familial hematophagocytic lymphohistiocytosis. The pathology of these patients has dramatically illustrated an under-appreciated role for perforin in the regulation of T-cell responses in vivo, and experimental studies are shedding light on the mechanisms involved. The detailed molecular mechanisms of perforin's mandatory role in the cytotoxic T lymphocyte (CTL)-mediated granule exocytosis death pathway and of granzyme entry into target cells remain unclear. In model systems measuring apoptosis by granzyme B and sublytic perforin, pore formation is undetectable during granzyme entry. Selfprotection of cytotoxic lymphocytes after degranulation can be explained by surface expression of the granule protease cathepsin B, as shown by suicidal degranulation in the presence of specific inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499260     DOI: 10.1016/s0952-7915(03)00114-6

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  38 in total

Review 1.  Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy.

Authors:  Deborah M Brown
Journal:  Cell Immunol       Date:  2010-02-24       Impact factor: 4.868

2.  Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity.

Authors:  Glen C Ulett; Elisabeth E Adderson
Journal:  Curr Immunol Rev       Date:  2006-05

3.  Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis.

Authors:  E Rodríguez-Martín; C Picón; L Costa-Frossard; R Alenda; S Sainz de la Maza; E Roldán; M Espiño; L M Villar; J C Álvarez-Cermeño
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

4.  Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure.

Authors:  Alexandre Harari; Felicitas Bellutti Enders; Cristina Cellerai; Pierre-Alexandre Bart; Giuseppe Pantaleo
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

5.  Cationic sites on granzyme B contribute to cytotoxicity by promoting its uptake into target cells.

Authors:  Catherina H Bird; Jiuru Sun; Kheng Ung; Diana Karambalis; James C Whisstock; Joseph A Trapani; Phillip I Bird
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

6.  Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects.

Authors:  Hyun-Il Cho; Esteban Celis
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

7.  Granzyme B production distinguishes recently activated CD8(+) memory cells from resting memory cells.

Authors:  Tobias M Nowacki; Stefanie Kuerten; Wenji Zhang; Carey L Shive; Christian R Kreher; Bernhard O Boehm; Paul V Lehmann; Magdalena Tary-Lehmann
Journal:  Cell Immunol       Date:  2007-09-07       Impact factor: 4.868

8.  Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells.

Authors:  George Makedonas; Natalie Hutnick; Danielle Haney; Alexandra C Amick; Jay Gardner; Gabriela Cosma; Adam R Hersperger; Douglas Dolfi; E John Wherry; Guido Ferrari; Michael R Betts
Journal:  PLoS Pathog       Date:  2010-03-05       Impact factor: 6.823

Review 9.  Cytokine production and dysregulation in HIV pathogenesis: lessons for development of therapeutics and vaccines.

Authors:  Morgan A Reuter; Carolina Pombo; Michael R Betts
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

10.  CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions.

Authors:  Toshimichi Matsui; John E Connolly; Mark Michnevitz; Damien Chaussabel; Chun-I Yu; Casey Glaser; Sasha Tindle; Marc Pypaert; Heidi Freitas; Bernard Piqueras; Jacques Banchereau; A Karolina Palucka
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.